Time: 2024-07-17
Democratic U.S. Senate aides are scheduled to meet with Novo Nordisk executives on Tuesday to discuss the fallout from the company 's decision to stop selling one of its long - acting insulins in the United States . Senators Jeanne Shaheen , Raphael Warnock , and Elizabeth Warren will have representatives present at the meeting . This decision , announced in November , stated that Novo Nordisk would permanently discontinue Levemir by the end of 2024 . Although Novo Nordisk claims to have provided patients with enough time to switch to other options , there is uncertainty regarding the production of a biosimilar version of the insulin.
European health authorities have issued a warning regarding patients who are due to undergo surgery while being treated with diabetes and weight loss drugs from Novo Nordisk and Eli Lilly . The safety committee of the European Medicines Agency has advised patients treated with GLP-1 drugs to inform their doctors before undergoing surgeries involving general anesthesia or deep sedation . The agency highlighted a potential risk of aspiration of stomach contents for patients under anesthesia and taking such medication , despite not finding a causal association . Product information will be updated to reflect this risk.
Democratic U.S. Senate aides are scheduled to meet with Novo Nordisk executives to discuss the company 's decision to discontinue the sale of one of its long - acting insulins in the United States . This decision , announced in November , has raised concerns among lawmakers , who have urged Novo Nordisk to reconsider . European health authorities have also issued a warning regarding patients undergoing surgery while being treated with diabetes and weight loss drugs from Novo Nordisk and Eli Lilly , citing a potential risk of anesthesia complications . Patients are advised to inform their doctors before undergoing surgeries involving general anesthesia or deep sedation.
Democratic U.S. Senate aides are set to meet with Novo Nordisk executives to address the repercussions of the company 's decision to halt the sale of one of its long - acting insulins in the United States . This decision , announced in November , has sparked concerns among lawmakers , prompting them to engage in discussions with the pharmaceutical company . Additionally , European health authorities have raised alarms about the potential risks associated with undergoing surgery while being treated with diabetes and weight loss drugs from Novo Nordisk and Eli Lilly . Patients are advised to communicate with their healthcare providers before undergoing surgeries involving general anesthesia or deep sedation .
The decision by Novo Nordisk to cease the sale of one of its long - acting insulins in the United States has garnered attention from Democratic U.S. Senate aides , who are scheduled to meet with company executives to address the issue . This move , announced in November , has prompted concerns among lawmakers , leading to calls for Novo Nordisk to reconsider its decision . In a separate development , European health authorities have issued a warning about the potential risks of anesthesia complications for patients undergoing surgery while being treated with diabetes and weight loss drugs from Novo Nordisk and Eli Lilly . Patients are advised to inform their doctors before undergoing surgeries involving general anesthesia or deep sedation.
Business
